Maintenance Olaparib in Newly Diagnosed Advanced Ovarian Cancer
December 10, 2018
Does the addition of maintenance PARPi after initial therapy in high-grade ovarian carcinoma improve progression free survival?
Olaparib 300 mg PO bid x 2 years
High-grade serous or endometrioid ovarian cancer
mutation in BRCA1, BRCA2 (germline or somatic)
Olaparib vs Placebo:
median f/u: 41 mos
3yrs PFS: 60% vs. 27% (SS)
Median time to subsequent therapy: 51.8 vs 15.1 months (SS)
Anemia G3/G4: 22% vs. 2% (SS)
Neutropenia G3/G4: 9% vs. 5% (SS)
AML: 1% vs. 0% (NS)
New Primary Cancer: 2% vs 2% (NS)
Pneumonitis/Interstitial Lung Disease: 2% vs. 0% (NS)
Addition of Olaparib for two years maintenance after completion of primary chemotherapy and debulking surgery in BRCA 1/2 (both germline or somatic) improves progression free survival.